GO:0055022 negative regulation of cardiac muscle tissue growth: Signaling Brakes, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0055022 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of cardiac muscle growth.
• It is a biological_process term that acts as a brake on cardiomyocyte hypertrophy, proliferation, and fibrotic remodeling in the heart.
• Key molecular players include TGF-beta1/SMAD3, SMAD7, FoxO3, FGF18, and circadian regulators that converge on cardiac growth control.
• Loss of negative regulation leads to pathological cardiac hypertrophy, heart failure, and adverse post-infarction remodeling.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test causality of candidate brakes in cardiomyocytes and fibroblasts.
• The term is experimentally studied using lineage tracing, transcriptomics, and functional assays in animal models and H9c2 cells.
Description
Cardiac muscle tissue growth is a tightly controlled process that determines heart size and function. While much attention is given to factors that promote cardiomyocyte growth, the mechanisms that restrain it are equally critical for preventing maladaptive remodeling. GO:0055022, negative regulation of cardiac muscle tissue growth, captures the biological processes that stop, prevent, or reduce the frequency, rate, or extent of cardiac muscle growth. This term is essential for understanding how the heart maintains homeostasis and how its dysregulation contributes to disease. Recent studies have identified multiple signaling pathways that act as brakes on cardiac growth. For example, TGF-beta1/SMAD3 signaling regulates programmed cell death 5 (PDCD5) to suppress cardiac fibrosis post-myocardial infarction by inhibiting HDAC3. Similarly, fibroblast Smad7 induction protects the pressure-overloaded heart by limiting remodeling. These findings highlight that negative regulation is an active, inducible process rather than a passive default. For researchers, GO:0055022 provides a framework to annotate genes and pathways that oppose cardiac hypertrophy, fibrosis, and regeneration. Understanding these mechanisms is vital for developing therapies that promote beneficial growth (e.g., regeneration) while preventing pathological growth (e.g., heart failure). This article synthesizes current knowledge on the genes, mechanisms, and experimental models used to study this process.
negative regulation of cardiac muscle tissue growth At A Glance
| GO ID | GO:0055022 |
|---|---|
| GO term | negative regulation of cardiac muscle tissue growth |
| Ontology | biological_process |
| Synonym | down regulation of cardiac muscle growth; down-regulation of cardiac muscle growth; downregulation of cardiac muscle growth; inhibition of cardiac muscle growth; negative regulation of heart muscle growth |
| Major function | Restrains cardiomyocyte hypertrophy, proliferation, and fibrotic remodeling to preserve cardiac homeostasis |
| Related processes | TGF-beta signaling, circadian regulation, FoxO3-mediated proliferation control, FGF18 signaling |
| Disease relevance | Pathological cardiac hypertrophy, heart failure, post-myocardial infarction remodeling |
| Experimental models | Knockout mice, transgenic overexpression, H9c2 cells, primary cardiomyocytes |
What Is GO:0055022?
GO:0055022, negative regulation of cardiac muscle tissue growth, is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of cardiac muscle growth. In practical terms, it encompasses molecular signals, cellular events, and physiological cues that limit the enlargement or proliferation of cardiac muscle cells, thereby maintaining heart size and function.
Why Is negative regulation of cardiac muscle tissue growth Important in Cell Biology?
Negative regulation of cardiac muscle tissue growth is critical because uncontrolled cardiac growth leads to pathological hypertrophy, fibrosis, and heart failure. The heart is a post-mitotic organ with limited regenerative capacity, so even small imbalances in growth regulation can have profound consequences. Understanding the molecular brakes that limit cardiac growth offers therapeutic opportunities to prevent or reverse maladaptive remodeling after injury or pressure overload.
• Prevents pathological cardiac hypertrophy and heart failure.
• Limits adverse fibrosis after myocardial infarction.
• Protects the pressure-overloaded heart from remodeling.
• Controls cardiomyocyte proliferation and regeneration capacity.
• Integrates circadian rhythms with cardiac growth control.
• Regulates calcium-sarcomere interplay during cardiomyocyte maturation.
• Modulates cAMP-dependent contractility and heart failure development.
• Influences microRNA-mediated fibrosis in cardiac cells.
• Provides targets for therapeutic intervention in cardiac disease.
• Essential for maintaining cardiac homeostasis under stress.
What Happens During negative regulation of cardiac muscle tissue growth?
Initiation by stress or developmental cues
In simple terms: The heart senses stress or developmental signals and starts a program to limit growth.
Negative regulation of cardiac muscle growth is often initiated in response to biomechanical stress, neurohormonal signals, or developmental timing cues. For instance, pressure overload triggers fibroblast Smad7 induction, which acts as a protective brake on remodeling. Similarly, circadian regulators govern cardiac growth by modulating gene expression in a time-of-day-dependent manner. These initiating signals set off a cascade of molecular events that ultimately restrict cardiomyocyte enlargement or proliferation.
TGF-beta/SMAD signaling as a central brake
In simple terms: A major signaling pathway called TGF-beta puts the brakes on heart muscle growth.
The TGF-beta1/SMAD3 pathway plays a dual role in cardiac remodeling. It regulates PDCD5, which suppresses cardiac fibrosis post-myocardial infarction by inhibiting HDAC3. In fibroblasts, Smad7 induction protects the pressure-overloaded heart by attenuating TGF-beta signaling. These findings demonstrate that TGF-beta signaling can both promote and restrain cardiac growth depending on context and cell type, with SMAD7 acting as a key negative regulator.
FoxO3 and cell cycle control
In simple terms: FoxO3 stops heart muscle cells from dividing when growth needs to be limited.
FoxO3 controls cardiomyocyte proliferation and heart regeneration by regulating Sfrp2 expression in postnatal mice. This transcription factor acts as a negative regulator of cardiac growth by inhibiting cell cycle progression and promoting a quiescent state. Its activity is essential for proper heart development and for limiting regenerative responses that could become pathological.
FGF18 and anti-hypertrophic signaling
In simple terms: FGF18 is a molecule that reduces stress-induced heart enlargement.
Fibroblast growth factor 18 (FGF18) alleviates stress-induced pathological cardiac hypertrophy in male mice. FGF18 acts as a negative regulator by suppressing hypertrophic gene programs and reducing cardiomyocyte size. This highlights the role of growth factor signaling in restraining cardiac growth under pathological conditions.
Calcium-sarcomere interplay and maturation
In simple terms: Calcium and the heart's contractile machinery work together to control growth and maturation.
Interplay between calcium and sarcomeres directs cardiomyocyte maturation during regeneration. Proper calcium handling and sarcomere assembly are required for cardiomyocytes to exit the cell cycle and mature, which inherently limits further growth. Disruption of this interplay can lead to continued proliferation or pathological hypertrophy, underscoring the importance of negative regulation.
cAMP/PKA and contractility regulation
In simple terms: The cAMP/PKA pathway fine-tunes heart contraction and can also limit growth.
The RIalpha subunit of cAMP-dependent protein kinase (PKA) plays an essential role in regulating cardiac contractility and heart failure development. This pathway influences cardiomyocyte growth and function, with dysregulation leading to maladaptive remodeling. Negative regulation of cardiac growth is therefore intimately linked to contractile signaling and energy metabolism.
Key Genes Involved in GO:0055022 negative regulation of cardiac muscle tissue growth
The following genes and proteins have been experimentally implicated in negative regulation of cardiac muscle tissue growth, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMAD7 | Inhibits TGF-beta signaling in fibroblasts | Protects pressure-overloaded heart from remodeling |
| SMAD3 | Mediates TGF-beta1 signaling; regulates PDCD5 | Suppresses cardiac fibrosis post-MI via HDAC3 inhibition |
| PDCD5 | Programmed cell death 5; inhibits HDAC3 | Suppresses cardiac fibrosis post-myocardial infarction |
| HDAC3 | Histone deacetylase; promotes fibrosis | Target of PDCD5 in cardiac fibrosis |
| FoxO3 | Transcription factor; controls proliferation | Regulates Sfrp2 and heart regeneration |
| Sfrp2 | Secreted frizzled-related protein 2 | Mediates FoxO3 effects on cardiomyocyte proliferation |
| FGF18 | Fibroblast growth factor 18 | Alleviates stress-induced pathological cardiac hypertrophy |
| PKA RIalpha | Regulatory subunit of cAMP-dependent protein kinase | Essential for contractility and heart failure development |
| HCN1 | Hyperpolarization-activated cyclic nucleotide-gated channel 1 | Target of miR-411-5p in angiotensin II-induced fibrosis |
| MiR-411-5p | MicroRNA | Alleviates angiotensin II-induced fibrosis in H9c2 cells |
| Circadian regulators | Clock genes governing cardiac growth | Circadian governance of cardiac growth |
| Calcium-sarcomere components | Calcium handling and sarcomere proteins | Direct cardiomyocyte maturation during regeneration |
| TGF-beta1 | Cytokine; upstream of SMAD3 | Regulates PDCD5 and cardiac fibrosis |
| HDAC3 | Histone deacetylase 3 | Inhibited by PDCD5 to suppress fibrosis |
| Sfrp2 | Wnt signaling modulator | Regulated by FoxO3 in postnatal heart |
| FGF18 | Growth factor | Anti-hypertrophic signaling in male mice |
| PKA RIalpha | cAMP-dependent protein kinase subunit | Regulates cardiac contractility and failure |
How Is negative regulation of cardiac muscle tissue growth Regulated?
Negative regulation of cardiac muscle tissue growth is itself regulated at multiple levels. TGF-beta1/SMAD3 signaling induces PDCD5, which in turn inhibits HDAC3 to suppress fibrosis. Smad7 induction in fibroblasts provides a negative feedback loop that protects the pressure-overloaded heart. Circadian clocks govern cardiac growth by modulating gene expression in a time-dependent manner. FoxO3 activity is controlled by upstream signaling pathways that respond to stress and nutrient availability. FGF18 signaling is induced under stress and acts as an anti-hypertrophic factor. The cAMP/PKA pathway, through its RIalpha subunit, regulates contractility and heart failure development, indirectly influencing growth. These regulatory layers ensure that cardiac growth is precisely tuned to physiological demands.
negative regulation of cardiac muscle tissue growth and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FGF18 | Pathological cardiac hypertrophy | Knockout and overexpression mice |
| PKA RIalpha | Heart failure and contractility defects | Cardiomyocyte-specific knockout |
| PDCD5 | Cardiac fibrosis post-myocardial infarction | Overexpression and knockout in fibroblasts |
| SMAD7 | Pressure-overload remodeling | Fibroblast-specific knockout |
| FoxO3 | Cardiomyocyte proliferation and regeneration | Inducible knockout in postnatal mice |
Pathological cardiac hypertrophy and heart failure
Loss of negative regulation of cardiac muscle growth contributes to pathological hypertrophy and heart failure. FGF18 alleviates stress-induced pathological cardiac hypertrophy in male mice, indicating that its downregulation or dysfunction may exacerbate disease. Similarly, the RIalpha subunit of PKA is essential for regulating cardiac contractility and heart failure development; its dysregulation leads to maladaptive remodeling. These findings suggest that enhancing negative regulatory pathways could be therapeutic.
Post-myocardial infarction remodeling and fibrosis
After myocardial infarction, TGF-beta1/SMAD3 signaling regulates PDCD5, which suppresses cardiac fibrosis by inhibiting HDAC3. Fibroblast Smad7 induction protects the pressure-overloaded heart from adverse remodeling. These studies demonstrate that negative regulation of cardiac growth and fibrosis is critical for preventing heart failure post-injury.
Cardiomyocyte proliferation and regeneration
FoxO3 controls cardiomyocyte proliferation and heart regeneration by regulating Sfrp2 expression in postnatal mice. This negative regulatory mechanism limits regenerative capacity, which may be beneficial in preventing tumor-like growth but detrimental for heart repair. Understanding this balance is key for regenerative medicine.
Angiotensin II-induced fibrosis
MiR-411-5p alleviates angiotensin II-induced fibrosis in H9c2 cells by inhibiting HCN1. This microRNA-mediated pathway represents a negative regulatory mechanism that restrains fibrotic growth in cardiac cells, highlighting potential therapeutic targets.
From negative regulation of cardiac muscle tissue growth-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate cardiac growth? | CRISPR knockout in cardiomyocytes or mice |
| Does a point mutation in gene X alter its function? | CRISPR point mutation (e.g., kinase-dead, phospho-mutant) |
| Does tagging gene X affect its localization? | CRISPR knock-in of fluorescent or epitope tag |
| Does overexpression of gene X suppress hypertrophy? | Transgenic overexpression or viral delivery |
| Which genes cooperate in negative regulation? | CRISPR library screening in cardiac cells |
| What are the transcriptomic changes? | RNA-seq after gene perturbation |
How to Study the negative regulation of cardiac muscle tissue growth Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify pathways altered by negative regulators |
| Single-cell RNA-seq | Cell-type-specific expression | Dissect fibroblast vs cardiomyocyte responses |
| Immunofluorescence | Protein localization and cell size | Measure cardiomyocyte hypertrophy |
| EdU incorporation | DNA synthesis / proliferation | Assess cardiomyocyte proliferation |
| Masson's trichrome | Fibrosis area | Quantify cardiac fibrosis |
| Western blot | Protein expression and phosphorylation | Validate signaling changes |
| CRISPR screening | Gene function at scale | Discover novel negative regulators |
Transcriptomic profiling
RNA-seq and single-cell RNA-seq are used to identify genes and pathways that are differentially expressed during negative regulation of cardiac growth. For example, FoxO3 regulates Sfrp2 expression, which can be detected by transcriptomic analysis. Circadian governance of cardiac growth has been studied using time-series transcriptomics.
Functional assays for cardiomyocyte growth
Cardiomyocyte size, proliferation, and apoptosis are measured using immunofluorescence, EdU incorporation, and TUNEL assays. FGF18 effects on hypertrophy were assessed by measuring cardiomyocyte cross-sectional area. Calcium-sarcomere interplay during maturation was studied using live imaging and functional assays.
Histology and fibrosis quantification
Masson's trichrome and Sirius red staining are used to quantify fibrosis in heart tissue. PDCD5-mediated suppression of cardiac fibrosis was demonstrated using these methods. Smad7 induction in pressure-overloaded hearts was also evaluated histologically.
CRISPR-based perturbation
CRISPR knockout, knock-in, and overexpression models enable causal testing of candidate genes. For instance, cardiomyocyte-specific knockout of FoxO3 was used to study proliferation. CRISPR screens can identify novel negative regulators of cardiac growth in an unbiased manner.
How CRISPR Can Be Used to Study GO:0055022 negative regulation of cardiac muscle tissue growth
Knockout
CRISPR knockout is used to delete candidate negative regulators of cardiac growth in cardiomyocytes or mice. For example, knockout of FoxO3 leads to increased cardiomyocyte proliferation, confirming its role as a brake. Fibroblast-specific Smad7 knockout exacerbates pressure-overload remodeling. These models provide causal evidence for gene function.
Point Mutation
CRISPR point mutation introduces specific amino acid changes to dissect functional domains. For instance, mutating phosphorylation sites in FoxO3 or SMAD3 can reveal how post-translational modifications affect their negative regulatory activity. This approach is valuable for understanding signaling mechanisms.
Knock-in
CRISPR knock-in of tags (e.g., GFP, HA) or reporter genes allows visualization and tracking of negative regulators in vivo. Tagging endogenous FoxO3 or SMAD7 enables real-time imaging of their localization and dynamics during cardiac growth.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression is used to increase levels of negative regulators. Overexpression of FGF18 alleviates pathological cardiac hypertrophy, and overexpression of PDCD5 suppresses fibrosis. These models test sufficiency of candidate genes.
How EDITGENE Supports negative regulation of cardiac muscle tissue growth Research
Researchers studying negative regulation of cardiac muscle tissue growth-related genes often need to determine whether a candidate gene is causally involved in restraining cardiomyocyte hypertrophy, proliferation, or fibrosis. EDITGENE provides comprehensive CRISPR services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cardiac muscle tissue growth research.
Frequently Asked Questions About negative regulation of cardiac muscle tissue growth
What is GO:0055022?
GO:0055022 is the Gene Ontology term for negative regulation of cardiac muscle tissue growth, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of cardiac muscle growth.
What genes are involved in negative regulation of cardiac muscle tissue growth?
Key genes include SMAD7, SMAD3, PDCD5, FoxO3, Sfrp2, FGF18, PKA RIalpha, and HCN1, as identified in recent studies.
How does TGF-beta signaling negatively regulate cardiac growth?
TGF-beta1/SMAD3 regulates PDCD5, which suppresses cardiac fibrosis by inhibiting HDAC3. Smad7 induction in fibroblasts also protects the pressure-overloaded heart.
What is the role of FoxO3 in cardiac growth?
FoxO3 controls cardiomyocyte proliferation and heart regeneration by regulating Sfrp2 expression in postnatal mice.
How is FGF18 involved in cardiac hypertrophy?
FGF18 alleviates stress-induced pathological cardiac hypertrophy in male mice.
What experimental models are used to study negative regulation of cardiac muscle growth?
Common models include CRISPR knockout mice, transgenic overexpression, primary cardiomyocytes, and H9c2 cells.
What diseases are associated with dysregulation of this process?
Pathological cardiac hypertrophy, heart failure, post-myocardial infarction remodeling, and fibrosis.
How does the circadian clock regulate cardiac growth?
Circadian governance of cardiac growth involves time-of-day-dependent gene expression that modulates growth pathways.
What is the role of calcium-sarcomere interplay in cardiomyocyte maturation?
Interplay between calcium and sarcomeres directs cardiomyocyte maturation during regeneration, limiting further growth.
How can CRISPR be used to study negative regulation of cardiac muscle growth?
CRISPR knockout, point mutation, knock-in, and overexpression enable causal testing of candidate genes in cardiac cells and animal models.
Conclusion
GO:0055022, negative regulation of cardiac muscle tissue growth, represents a critical biological process that restrains cardiomyocyte hypertrophy, proliferation, and fibrosis. Key genes such as SMAD7, FoxO3, FGF18, and PDCD5 have been shown to act as brakes on cardiac growth, with dysregulation leading to heart failure and adverse remodeling. Understanding these mechanisms offers therapeutic opportunities to prevent or reverse cardiac disease. EDITGENE provides comprehensive CRISPR services to accelerate research in this field.
References
- 1. Weng L et al.. 2023. TGF-β1/SMAD3 Regulates Programmed Cell Death 5 That Suppresses Cardiac Fibrosis Post-Myocardial Infarction by Inhibiting HDAC3.. Circ Res 133(3):237-251 PMID: 37345556
- 2. Humeres C et al.. 2024. Fibroblast Smad7 Induction Protects the Remodeling Pressure-Overloaded Heart.. Circ Res 135(3):453-469 PMID: 38899461
- 3. Latimer MN et al.. 2022. Circadian Governance of Cardiac Growth.. Cells 11(9) PMID: 35563800
- 4. Nguyen PD et al.. 2023. Interplay between calcium and sarcomeres directs cardiomyocyte maturation during regeneration.. Science 380(6646):758-764 PMID: 37200435
- 5. Xia JB et al.. 2025. FoxO3 controls cardiomyocyte proliferation and heart regeneration by regulating Sfrp2 expression in postnatal mice.. Nat Commun 16(1):2532 PMID: 40087279
- 6. Chen G et al.. 2023. Fibroblast growth factor 18 alleviates stress-induced pathological cardiac hypertrophy in male mice.. Nat Commun 14(1):1235 PMID: 36871047
- 7. Bedioune I et al.. 2024. Essential Role of the RIα Subunit of cAMP-Dependent Protein Kinase in Regulating Cardiac Contractility and Heart Failure Development.. Circulation 150(25):2031-2045 PMID: 39355927
- 8. Tian C et al.. 2025. MiR-411-5p Alleviates Angiotensin II-Induced Fibrosis in H9c2 Cells by Inhibiting HCN1.. Int Heart J 66(5):852-861 PMID: 41034030
